Technical Analysis for KERX - Keryx Biopharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 3.36 -2.04% -0.07
KERX closed down 2.04 percent on Wednesday, December 12, 2018, on 2.07 times normal volume. It was able to find support at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical KERX trend table...

Date Alert Name Type % Chg
Dec 12 20 DMA Support Bullish 0.00%
Dec 12 50 DMA Support Bullish 0.00%
Dec 12 Wide Range Bar Range Expansion 0.00%
Dec 12 Upper Bollinger Band Walk Strength 0.00%
Dec 12 Wide Bands Range Expansion 0.00%
Dec 12 Overbought Stochastic Strength 0.00%
Dec 12 Upper Bollinger Band Touch Strength 0.00%
Dec 11 Above Upper BB Strength -2.04%
Dec 11 Overbought Stochastic Strength -2.04%
Dec 11 Upper Bollinger Band Touch Strength -2.04%

Older signals for KERX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States. It is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes. The company has completed Phase III clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease on dialysis. Zerenex is also in Phase II development for the management of phosphorus and iron deficiency in anemic patients with stages three to five non-dialysis dependent chronic kidney diseases. The company has sublicense agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Zerenex in Japan. It also has strategic alliances with Panion & BF Biotech, Inc.; Japan Tobacco Inc.; and Torii Pharmaceutical Co., Ltd. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in New York, New York.
Is KERX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.98
52 Week Low 2.47
Average Volume 1,263,973
200-Day Moving Average 3.9651
50-Day Moving Average 3.0344
20-Day Moving Average 2.9695
10-Day Moving Average 3.155
Average True Range 0.2495
ADX 21.95
+DI 27.3469
-DI 17.7301
Chandelier Exit (Long, 3 ATRs ) 2.9015
Chandelier Exit (Short, 3 ATRs ) 3.2185
Upper Bollinger Band 3.4307
Lower Bollinger Band 2.5083
Percent B (%b) 0.92
BandWidth 31.062468
MACD Line 0.092
MACD Signal Line 0.0267
MACD Histogram 0.0653
Fundamentals Value
Market Cap 399 Million
Num Shares 119 Million
EPS -1.72
Price-to-Earnings (P/E) Ratio -1.95
Price-to-Sales 15.33
Price-to-Book 25.60
PEG Ratio -0.04
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.11
Resistance 3 (R3) 4.06 3.76 3.99
Resistance 2 (R2) 3.76 3.57 3.79 3.94
Resistance 1 (R1) 3.56 3.45 3.41 3.61 3.90
Pivot Point 3.26 3.26 3.19 3.29 3.26
Support 1 (S1) 3.06 3.07 2.91 3.11 2.82
Support 2 (S2) 2.76 2.95 2.79 2.78
Support 3 (S3) 2.56 2.76 2.74
Support 4 (S4) 2.61